Market Research Report
G-Protein Coupled Receptors (GPCR) Market - Growth, Trends, and Forecasts (2020 - 2025)
|Published by||Mordor Intelligence Pvt Ltd||Product code||907036|
|Published||Content info||110 Pages
Delivery time: 2-3 business days
|G-Protein Coupled Receptors (GPCR) Market - Growth, Trends, and Forecasts (2020 - 2025)|
|Published: June 1, 2020||Content info: 110 Pages||
G-protein coupled receptors market is anticipated to be driven by rising number of cancer cases, rising prevalence of lifestyle-related issues, such as cardiovascular infections, and respiratory issues. G-protein coupled receptors (GPCRs) are exceptionally helpful in the innovative work of newer medication substances. Furthermore, the increasing government funding for R&D activities in drug discovery and development is anticipated to drive the market growth. Additionally, the functional and structural literature on the pharmacological components of the GPCRs is demonstrating the adaptable utilities of GPCRs targets in the treatment of an expansive range of disorders which helps the market expand. The high cost involved in the maintenance of GPCR cell lines impedes the growth of the G-protein coupled receptors (GPCR) market.
Oncology Estimated to Dominate the Global G-Protein Coupled Receptors (GPCR) Market, by Therapeutic Areas
More than 700 genes are identified as the G-protein coupled receptors, which form the largest protein superfamily in the human genome. GPCRs play a vital role in interfering with a wide variety of physiological events, from sensory modulations to hormonal responses. Recently, a key focus on basic and clinical investigators demonstrated that signaling through GPCRs affects the various aspects of cancer biology, such as invasion, migration, and vascular remolding. Hence, the development of GPCR-targeted drugs will provide a novel therapeutic strategy in treating various types of cancers. As GPCR signaling is an important contributor to tumor growth and metastasis, discerning how G protein-coupled receptor kinases (GRKs) regulate GPCR activity in cancer cells may greatly improve the understanding of tumorigenesis and oncogenesis, and help develop novel anti-cancer therapies.
Asia-Pacific is Anticipated to Register a Rapid CAGR
The Asia-Pacific region is expected to grow at a significant rate during the forecast period, owing to the economic development of the countries, such as China and India, along with the increasing government investment in the biotechnology and biopharmaceutical sector, increasing life expectancy, rising per capita income, and unmet market needs in the region. Additionally, Asia Pacific is anticipated to be the fastest-growing regional market due to the presence of several emerging companies, such as Sosei Heptares, HD Biosciences Co., Ltd., and NB Health Laboratory. The number of growth initiatives undertaken by the companies to improve their market presence drives regional growth.
The players in global G-protein coupled receptors (GPCR) market are focusing on the expansion of their product portfolios, by adopting inorganic growth strategies, such as acquisitions, mergers, and partnerships. For instance, in June 2018, Amgen's erenumab secured the FDA approval as the first G-protein coupled receptor-targeted antibody. Despite various challenges, several biologics are under the manufacturing process.